Phase II Study of SOX in Patients With Platinum-resistant Nasopharyngeal Carcinoma
The treatment option in patients with platinum-resistant relapsed or metastatic
nasopharyngeal carcinoma is limited. Previous studies showed that both S-1 and oxaliplatin
were effective in head and neck cancer. Moreover, SOX (S-1 plus oxaliplatin) was proved to
be tolerable in advanced stage gastric cancer. Therefore, we aim to evaluate this regimen in
salvage setting of nasopharyngeal carcinoma.
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Median progression-free survival
1 year
No
Ye Guo, MD
Principal Investigator
Fudan University
China: Ethics Committee
HNTG 11-02
NCT01403259
July 2011
December 2013
Name | Location |
---|